Immunomedics Email Format
Biotechnology ResearchNew Jersey, United States51-200 Employees
Immunomedics is a mid-sized biotechnology company specializing in next-generation antibody-drug conjugate (ADC) technology, focusing on cancers that are difficult to treat. Based in Morris Plains, New Jersey, the firm works on ADC-based approaches intended to improve treatment options for patients with challenging cancers. Its activities sit squarely in the biotechnology research field, emphasizing targeted cancer therapies built around antibody-drug conjugates. In 2022, Immunomedics announced a collaboration with Hoffmann-La Roche to advance clinical trials of Trodelvy. The partnership demonstrates ongoing collaboration with pharmaceutical companies to develop oncology programs. This external collaboration reflects the company's engagement in the oncology field and its focus on partnerships to advance its pipeline.